Science Explorer Back to mapMap
Discussion
Topic · Cardiology and Cardiovascular Medicine

Chemotherapy-induced cardiotoxicity and mitigation

Chemotherapy-induced cardiotoxicity and mitigation is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 14k research works in it since 1956. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.

  • Anthracyclines
  • Doxorubicin
  • Cardiomyopathy
  • Chemotherapy
  • Cardiovascular Complications
  • Trastuzumab
  • Oxidative Stress
  • Cardiac Dysfunction
  • Prevention
  • Survivors
Research works
14k
fractional, since 1956
In the world top 10%
1.4k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+35%
the tick is no change
Largest producer
United States
38% of the 10 largest, 2022-now
Chemotherapy-induced cardiotoxicity and mitigation

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Chemotherapy-induced cardiotoxicity and mitigation research?

By volume, the United States and China publish the most (1.1k and 719 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.1k works
  2. 2 China 719 works
  3. 3 Italy 201 works
  4. 4 Japan 198 works
  5. 5 United Kingdom 141 works
  6. 6 India 139 works
  7. 7 Türkiye 107 works
  8. 8 Canada 104 works
  9. 9 Brazil 102 works
  10. 10 Egypt 98 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 37.7%China: 24.8%Italy: 6.9%Japan: 6.8%6 others listed: 23.8%38%largest
United States1,094 · 37.7%China719 · 24.8%Italy201 · 6.9%Japan198 · 6.8%6 others listed690 · 23.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Chemotherapy-induced cardiotoxicity and mitigation research?

By volume in 2022-now, Harvard University publishes the most Chemotherapy-induced cardiotoxicity and mitigation research, followed by Mayo Clinic and The University of Texas MD Anderson Cancer Center.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 47 works
  2. 2 Mayo ClinicUnited States 41 works
  3. 3 The University of Texas MD Anderson Cancer CenterUnited States 28 works
  4. 4 University of TorontoCanada 20 works
  5. 5 University of PennsylvaniaUnited States 19 works
  6. 6 Shanghai Jiao Tong UniversityChina 19 works
  7. 7 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 19 works
  8. 8 The Ohio State UniversityUnited States 16 works
  9. 9 InsermFrance 16 works
  10. 10 Sichuan UniversityChina 16 works

Who are the leading researchers in Chemotherapy-induced cardiotoxicity and mitigation?

The most-cited researchers publishing on Chemotherapy-induced cardiotoxicity and mitigation include Ahmedin Jemal, Rebecca L. Siegel and John J.V. McMurray.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Rebecca L. Siegel United States 582k citations
  3. 3 John J.V. McMurray United Kingdom 349k citations
  4. 4 Hermann Brenner Germany 343k citations
  5. 5 Stephan Windecker Switzerland 338k citations
  6. 6 Elie A. Akl Canada 313k citations
  7. 7 Gregory Y.H. Lip United Kingdom 311k citations
  8. 8 Peter Jüni Switzerland 303k citations
  9. 9 Naohiro Yonemoto Japan 297k citations
  10. 10 Salim Yusuf Canada 294k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Chemotherapy-induced cardiotoxicity and mitigation?

The most cited paper in Chemotherapy-induced cardiotoxicity and mitigation is "Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer" (Sarah C. Darby, Marianne Ewertz, Paul McGale et al., 2013), with 4,034 citations. Next come "Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity" (3,790) and "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)" (3,050).

Most cited papers
#PaperReleasedCitations
1 Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer Sarah C. Darby, Marianne Ewertz, Paul McGale et al. · New England Journal of Medicine Open access 13 Mar 2013 4,034
2 Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli et al. · Pharmacological Reviews 28 May 2004 3,790
3 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Alexander Richard Lyon et al. · European Heart Journal Open access167 authors 26 Aug 2022 3,050
4 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines José Luis Zamorano et al. · European Heart Journal Open access 24 Aug 2016 2,586
5 Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer Agnes Y. Y. Lee, Mark N. Levine, Ross Ian Baker et al. · New England Journal of Medicine Open access 9 Jul 2003 2,541
All 96 most cited papers, with filters and sorting

Where is Chemotherapy-induced cardiotoxicity and mitigation research done?

The largest centres of Chemotherapy-induced cardiotoxicity and mitigation research in 2022-now are Beijing (China), Shanghai (China), Moscow (Russia) and London (United Kingdom).

Largest cities, 2022-now

  1. 1 BeijingChina 79 works
  2. 2 ShanghaiChina 58 works
  3. 3 MoscowRussia 50 works
  4. 4 LondonUnited Kingdom 49 works
  5. 5 GuangzhouChina 48 works
  6. 6 New YorkUnited States 47 works
  7. 7 HoustonUnited States 46 works
  8. 8 BostonUnited States 45 works
  9. 9 TokyoJapan 45 works
  10. 10 SeoulSouth Korea 39 works
See Chemotherapy-induced cardiotoxicity and mitigation on the map

Where is the best place to study Chemotherapy-induced cardiotoxicity and mitigation?

Among universities, judged by research, Harvard University, Beijing University of Chinese Medicine and Chiang Mai University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.25%fractional works in this field (log) →share of work in the world top 10% →Beijing University o…Chiang Mai UniversityUniversity of TorontoHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 72.415.7%3.9×47 +22.7%
2Beijing University of Chinese MedicineChina 63.034.5%10.6×9 +159.9%
3Chiang Mai UniversityThailand 57.017.8%13.4×16 +139.8%
4University of TorontoCanada 48.816.7%2.7×20 -7.3%
5University of PennsylvaniaUnited States 46.813.6%4.7×19 +9.9%
6Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 46.315.3%4.7×18 +38.0%
7Fujian Medical UniversityChina 45.525.4%4.5×9 +218.7%
8Wuhan UniversityChina 44.215.9%2.9×15 +3.4%
9Nanchang UniversityChina 43.617.4%3.4×10 +143.9%
10Fudan UniversityChina 41.920.2%1.9×11 +60.0%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Chemotherapy-induced cardiotoxicity and mitigation, country by country

Is Chemotherapy-induced cardiotoxicity and mitigation research growing?

Output in 2022-2025 was 35% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Chemotherapy-induced cardiotoxicity and mitigation.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Chemotherapy-induced cardiotoxicity and mitigation as a percentage of every work published that year, 0.016% in 2024.

still counting0.010%0.020%0.030%Chemotherapy-induced cardiotoxicity and mitigation0.020% in 202519801990200020102020

Fractional works of Chemotherapy-induced cardiotoxicity and mitigation over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Chemotherapy-induced cardiotoxicity and mitigation9.8% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Chemotherapy-induced cardiotoxicity and mitigation. Posts are plain text and can be reported.